RAINFALLs On Lilly's Cyramza Stomach Cancer Parade
A lack of overall survival benefit in first-line stomach cancer in a Phase III trial has scuppered Eli Lilly's hopes of expanding Cyramza's use into a new and relatively empty market.
You may also be interested in...
Studied with Tarceva, Cyramza showed an ability to improve PFS in patients with EGFR-mutant tumors. But how will a two-company combo fare against Tagrisso monotherapy?
An improvement in overall survival seen in the Phase III TAGS study and a unique mechanism of action augurs well for Taiho/Servier's Lonsurf gaining gastric cancer as an additional indication, but future competitive pressures are likely to be intense in this therapeutic sector.
Disappointing outcome for the companies' PD-L1 inhibitor avelumab in late-stage gastric cancer may not have implications for the drug in more valuable indications, like lung cancer.